Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Law Offices of Todd M. Garber Announces Class Action Lawsuit Against Delcath Systems, Inc.

Law Offices of Todd M. Garber Announces Class Action Lawsuit Against Delcath Systems, Inc.

LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Todd M. Garber announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of a class (the “Class”) comprising all purchasers of the securities of Delcath Systems, Inc. (“Delcath” or the “Company”) (Nasdaq: DCTH  ) between April 21, 2010 and May 2, 2013, inclusive (the “Class Period”).

Delcath operates as a specialty pharmaceutical and medical device company focusing on the field of oncology, primarily the development of CHEMOSAT/Melblez Kit system, which administers concentrated regional chemotherapy to the liver. The Complaint alleges that defendants misrepresented or failed to disclose material adverse facts about the Company's New Drug Application seeking Food and Drug Administration (FDA) approval for commercial sale of Melblez Kit -- Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System -- for the treatment of patients with unresectable ocular melanoma metastatic to the liver, including substantial and severe toxicity, and deaths associated with the drug’s adverse reactions.

On May 2, 2013 the Company disclosed that the FDA’s Oncologic Drugs Advisory Committee voted 16-0, with no abstentions, that Melblez Kit’s treatment benefits do not outweigh the risks associated with the procedure. The next day, as a result of this news, the price of Delcath shares dropped more than 40% on extremely heavy trading volume.

If you are a member of the above-described Class, you may move the Court no later than July 8, 2013 to serve as lead plaintiff; however, you must meet certain legal requirements. To be a member of the Class you need not take any action at this time, or you may retain counsel of your choice. If you have information or would like to learn more about these claims, or if you purchased Delcath stock prior to the Class Period and have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Todd M. Garber, Esquire, of the Law Offices of Todd M. Garber, by telephone at 213-700-7262 or by email to

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Law Offices of Todd M. Garber
Todd M. Garber, Attorney at Law

KEYWORDS:   United States  North America  California


Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2492824, ~/Articles/ArticleHandler.aspx, 10/9/2015 10:29:38 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...